{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"75","value":"20"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"78","value":"3"}]}],"title":"6 mo (TMS=28; AC= 28)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7","upperLimit":"79","value":"17"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"79","value":"6"}]}],"title":"12 mo (TMS=25; AC= 21)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"60","value":"16"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"65","value":"6"}]}],"title":"24 mo (TMS=18; AC= 13)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"The percentage of CCR7+CD45RA+ naïve T cells within the CD4 and CD8 T cell populations was determined by flow cytometry.","dispersionType":"Full Range","groups":[{"description":"Rituximab:375 mg/m2 IV, day 1 for patients with CD20-positive disease. Allogenic stem cell transplant (ASCT):Conditioning Chemotherapy:Fludarabine:30 mg/m2 per day IV infusion over 30 minutes, daily On days -6, -5, -4, and -3. Cyclophosphamide:1200 mg/m2 per day IV infusion over 2 hours on Days 6, -5, -4, -3.Mesna: 1200 mg/m2 per day IV infusion, Daily on days 6, -5,-4, and -3.Tacrolimus: 0.02 mg/kg, start day 3. Continue IV or PO. Taper will begin at day +63 if no acute GVHD then at day +119 and discontinue at day +180 as tolerated. Methotrexate: 5mg/m2 IV over 15 minutes on days 1, 3, 6, and 11. Sirolimus: 12 mg PO on days -3 to 63, followed by a taper if GVHD does not develop. Sirolimus: 12 mg PO on days -3 to 63, followed by a taper if GVHD does not develop.FLAG: Fludarabine:25 mg/m2 per day IV over 30 minutes, Daily on days 1-5. Cytarabine: 2,000 mg/m2 IV over 4 hours, on Days 1, 2, 3, 4, 5. Filgrastim: 5 mcg/kg per day SC beginning 24 hours PRIOR to initiation of chemotherapy","id":"OG000","title":"A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm"},{"description":"Rituximab375 mg/m2 IV, day 1 for pts with CD20-positive disease. Cyclosporine IV over 2 hrs or orally every 12 hrs on days -1-100, followed by a taper if GVHD does not develop. Allogenic stem cell transplant. Conditioning Chemotherapy Fludarabine:30 mg/m2 per day IV infusion over 30 min., daily on days -6, -5, -4, and -3. Cyclophosphamide1200 mg/m2 per day IV infusion over 2 hrs on Days 6, -5, -4, -3. Mesna1200 mg/m2 per day IV infusion, Daily on days 6, -5,-4, and -3. FLAG: Fludarabine25 mg/m2 per day IV over 30 min., Daily on days 1-5. Cytarabine 2,000 mg/m2 IV over 4 hrs, on Days 1, 2, 3, 4, 5. Filgrastim 5 mcg/kg per day SC beginning 24 hrs PRIOR to start of chemotherapy. EPOCH-F: Fludarabine25 mg/m2 per day IV infusion over 30 min., daily on days 1-4. Etoposide 50 mg/m2 per day continuous IV infusion over 24 hrs on days 1-4. Doxorubicin10 mg/m2/d. Grp 2 Alemtuzumab for 4 days starting 8 days before SCT + cyclosporine starting 1 day before SCT and continuing for 6 months.","id":"OG001","title":"B - Cyclosporine (AC) Arm"}],"paramType":"MEDIAN","populationDescription":"A few measurements were missed, one patient was not evaluable for technical reasons and removed from the analysis, but most of the decline was due to patients that had gone off study.","reportingStatus":"POSTED","timeFrame":"Recipient recovery at 6, 12 and 24 months post transplant","title":"Recovery of Naïve Cluster of Differentiation 8 (CD8) T Cells","type":"PRIMARY","unitOfMeasure":"% of naive (CCR7+CD45RA+) CD8 Cells"}